Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07671911 · ClinicalTrials.gov registry record · Phase 3
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
A Phase 3 study, sponsored by Trevi Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 306
- Enrollment target
NCT07671911: Recruiting Phase 3 study, sponsored by Trevi Therapeutics.
NCT07671911 is a Phase 3 study that is actively recruiting participants, run by Trevi Therapeutics. The registered enrollment target is 306 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07671911, a Phase 3 study, is actively recruiting participants, sponsored by Trevi Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 306 participants
- Enrollment target
Study Summary
The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with Idiopathic Pulmonary Fibrosis (IPF).
Interventions
- DRUG Placebo
- DRUG NAL ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 306 participants |
| Start Date | 2026-06-29 |
| Est. Completion | 2028-07 |
| Phase | Phase 3 |
What NCT07671911 shows while recruiting
NCT07671911 is an interventional study that assigns participants to a tested intervention. The registered 306 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07671911 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07671911 about?
NCT07671911 is a clinical study titled "Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets". The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with Idiopathic Pulmonary Fibrosis (IPF).
What is the current status of trial NCT07671911?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 306 participants. The study started on 2026-06-29. Estimated completion is 2028-07.
What interventions are being tested in trial NCT07671911?
The interventions under investigation include: Placebo (DRUG), NAL ER (DRUG).
Who is sponsoring clinical trial NCT07671911?
This trial is sponsored by Trevi Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07671911's enrollment target sits among peer trials
306 1115th of 2000 higher than 884 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05078970 · 306 participants · NA
Advancing Suicide Intervention Strategies for Teens During High Risk Periods
- NCT05843695 · 306 participants · NA
Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety
- NCT06057337 · 306 participants · NA
Families With Pride ("Familias Con Orgullo").
- NCT06498635 · 306 participants · Phase 3
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI